Page last updated: 2024-12-10

fenretinide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5288209
CHEMBL ID7301
CHEBI ID42588
CHEBI ID92493
SCHEMBL ID11704
SCHEMBL ID11703
SCHEMBL ID15703189
MeSH IDM0026291

Synonyms (135)

Synonym
smr001456303
HY-15373
AB00172992-07
mcn-r-1967
syt-101
st-602
4-hpr
EU-0100625
retinoic acid p-hydroxyanilide, >=95%
(2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide
LOPAC0_000625
2,6,8-nonatetraenamide, n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl-, (all-e)-
all-trans-4'-hydroxyretinanilide
fenretinide
nsc-374551
nsc374551
65646-68-6
n-(4-hydroxyphenyl)retinamide
mls002701698 ,
fenretinide (usan/inn)
D04162
SPECTRUM5_001939
BSPBIO_001419
IDI1_033889
4-(hydroxyphenyl)retinamide
NCGC00090752-01
MLS001055399
smr000677938
fenretinida [spanish]
brn 5769490
ccris 3260
fenretinidum [latin]
retinoic acid p-hydroxyphenylamide
fenretinide [usan:inn]
retinamide, n-(4-hydroxyphenyl)-
n-(4-hydroxyphenyl)all-trans retinamide
NCGC00090752-06
4hpr
NCGC00090752-04
4-hydroxyphenylretinamide
NCGC00090752-07
4-hydroxyphenyl retinamide
15-[(4-hydroxyphenyl)amino]retinal
HSCI1_000112
NCGC00090752-03
NCGC00090752-09
NCGC00090752-02
retinoic acid p-hydroxyanilide
NCGC00090752-05
HMS1989G21
H 7779
HMS2089B17
NCGC00090752-10
n-(4-hydroxyphenyl)retinamide, 4-hpr
3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide
n-(4-hydroxyphenyl)-retinamide
(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide
(2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide
bdbm50092055
CHEMBL7301 ,
rii retinamide
chebi:42588 ,
nsc-760419
BML2-E08
HMS1361G21
HMS1791G21
(2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
(2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide;fenretinide
A835178
NCGC00090752-11
HMS3261N12
NCGC00258542-01
tox21_200989
nsc760419
pharmakon1600-01505602
dtxcid0012005
cas-65646-68-6
dtxsid2032005 ,
tox21_111007
CCG-204713
unii-187ej7qexl
fenretinida
nsc 760419
187ej7qexl ,
fenretinidum
BP-13369
4-hydroxy(phenyl)retinamide
LP00625
CS-0789
S5233
DB05076
mfcd00792674
MLS006010811
SCHEMBL11704
SCHEMBL11703
NCGC00090752-12
tox21_111007_1
n-(4-hydroxyphenyl)-all-trans-vitamin a amide
fenretinide [vandf]
fenretinide [inn]
fenretinide [who-dd]
fenretinide [usan]
fenretinide [mart.]
fenretinide [mi]
H1464
tox21_500625
NCGC00261310-01
SCHEMBL15703189
15-(4-hydroxyanilino)retinal #
(2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide
AKOS024456572
HMS3402G21
all-trans-n-(4-hydroxyphenyl)retinamide
mk-4016
sr-01000075917
SR-01000075917-4
CHEBI:92493
AS-59667
SR-01000075917-1
fenretinide (4-hpr)
dimethyl-9-(2,6,6-trimethylcyclohex-
1-enyl)nona-2,4,6,8-tetraenamide
(2e,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-
p-hydroxyphenylretinamide
BCP06908
Q5443576
n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide
HMS3676M06
EX-A4102
calix[4!-bis-crown-6,95
HMS3412M06
SDCCGSBI-0050606.P002
NCGC00090752-20
AMY9087
fenretinide; 4-hpr

Research Excerpts

Overview

Fenretinide (4-HPR) is a synthetic derivative of all-trans-retinoic acid (ATRA) characterised by improved therapeutic properties and toxicological profile relative to ATRA. Fenretinid is an effective anti-cancer drug with high in vitro cytotoxi.

ExcerptReferenceRelevance
"Fenretinide (4-HPR) is a cytotoxic retinoid with clinical activity in recurrent neuroblastoma and venetoclax (ABT-199) is a selective inhibitor of the antiapoptotic protein B-cell lymphoma-2 (BCL-2)."( Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models.
Chen, WH; Kang, MH; Koneru, B; Makena, MR; Nguyen, TH; Reynolds, CP; Urias, E; Wei, SJ, 2019
)
2.68
"Fenretinide (Fen) is a novel agent, showing significant role in regulating oxidative stress and inflammatory response."( Fenretinide attenuates lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) and depressive-like behavior in mice by targeting Nrf-2 signaling.
Han, XH; Li, T; Zheng, LN, 2020
)
2.72
"Fenretinide (4-HPR) is a synthetic derivative of all-trans-retinoic acid (ATRA) characterised by improved therapeutic properties and toxicological profile relative to ATRA. "( Design, Synthesis, Radiosynthesis and Biological Evaluation of Fenretinide Analogues as Anticancer and Metabolic Syndrome-Preventive Agents.
Dall'Angelo, S; Mody, N; Patruno, I; Poot, AJ; Thompson, D; Vugts, DJ; Windhorst, AD; Zanda, M, 2020
)
2.24
"Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells. "( Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cho, H; Cooper, JP; Kang, MH; Reynolds, CP, 2017
)
2.2
"Fenretinide is a synthetic retinoid characterized by anticancer activity in preclinical models and favorable toxicological profile, but also by a low bioavailability that hindered its clinical efficacy in former clinical trials. "( A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors.
Baiocchi, M; Boe, A; Bongiorno-Borbone, L; Bruselles, A; Contavalli, P; Costantino, A; De Angelis, ML; De Maria, R; Eramo, A; Fecchi, K; Francescangeli, F; Giuliani, A; Kitamura, T; La Torre, F; Melino, G; Oki, T; Orienti, I; Peschiaroli, A; Salvati, V; Sette, G; Signore, M; Spada, M; Tartaglia, M; Zeuner, A; Zolla, L, 2019
)
2.29
"Fenretinide is a synthetic retinoid that has been evaluated in clinical trials as a cancer therapeutic and chemo-preventive agent."( Fenretinide: a novel treatment for endometrial cancer.
Bulun, SE; Coon, JS; Dyson, M; Kim, JJ; Malpani, S; Mittal, N; Ono, M; Pavone, ME; Schink, JC, 2014
)
2.57
"Fenretinide is an effective anti-cancer drug with high in vitro cytotoxicity and low in vivo systemic toxicity. "( Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles.
Bostanian, LA; Glotser, EY; Graves, RA; Ledet, GA; Mandal, TK, 2015
)
2.11
"Fenretinide is an anticancer drug with low water solubility and poor bioavailability. "( Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide.
Bostanian, LA; Glotser, EY; Graves, RA; Ledet, GA; Mandal, TK; Mitchner, DM, 2015
)
2.08
"Fenretinide (4-HPR) is a synthetic retinoid which acts on cancer cells through both nuclear retinoid receptor and non-receptor mechanisms."( Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
Carter, DR; Chesler, L; Cheung, BB; Haber, M; Kavallaris, M; Koach, J; Liu, B; Liu, T; Marshall, GM; Norris, MD; O'Neill, GM; Po'uha, ST; Shum, MS; Sutton, S; Tan, O, 2015
)
1.39
"Fenretinide is a retinoid that has shown preclinical activity in B-cell lymphomas."( Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Cowan, AJ; Frayo, SL; Gopal, AK; Green, DJ; Pagel, JM; Palanca-Wessels, MC; Press, OW, 2015
)
1.49
"Fenretinide (FEN) is a synthetic retinoid that inhibits obesity and insulin resistance in high-fat diet (HFD)-fed mice and completely prevents 3T3-L1 pre-adipocyte differentiation. "( Fenretinide mediated retinoic acid receptor signalling and inhibition of ceramide biosynthesis regulates adipogenesis, lipid accumulation, mitochondrial function and nutrient stress signalling in adipocytes and adipose tissue.
Delibegović, M; Doherty, MK; Grant, L; Maskrey, BH; Mcilroy, GD; Mody, N; Tammireddy, SR; Watson, DG; Whitfield, PD, 2016
)
3.32
"Fenretinide is a synthetic retinoid analogue that promotes apoptosis but has decreased toxicity when compared to other retinoids. "( Fenretinide: A Potential Treatment for Endometriosis.
Bulun, SE; Dyson, M; Kim, JJ; Malpani, SS; Pavone, ME, 2016
)
3.32
"Fenretinide (4-HPR) is a synthetic retinoid."( Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.
Chen, NE; Khankaldyyan, V; Maldonado, NV; Maurer, BJ; Reynolds, CP; Shimada, H; Song, MM, 2016
)
1.4
"Fenretinide is a novel anticancer agent reported to exhibit anti-invasive and antimetastatic activities. "( Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway.
Du, YF; Hung, HC; Lee, SY; Lin, CH; Ou, HY; Wu, HT; Zhang, CC, 2016
)
3.32
"Fenretinide is a synthetic retinoid that interferes with the attachment of retinol to retinol binding protein. "( Total rod ERG suppression with high dose compassionate Fenretinide usage.
Jain, A; Marmor, MF; Moshfeghi, D, 2008
)
2.04
"Fenretinide is a synthetic retinoid that is cytotoxic to a variety of cancers. "( Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
Chatta, G; Cheung, E; Dorff, T; Gandara, DR; Groshen, S; Lara, PN; Maurer, BJ; McNamara, M; Pinski, J; Quinn, DI; Reynolds, CP; Tsao-Wei, DD; Twardowski, P, 2009
)
2.31
"Fenretinide is a synthetic retinoid with activity in prostate cancer and other cell lines. "( A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.
Boyer, MJ; Lim, R; Millward, M; Mok, TS; Moore, MM; Stockler, M, 2010
)
2.13
"Fenretinide (4-HPR) is a retinoic acid analogue, currently used in clinical trials in oncology. "( Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.
Boddy, AV; Daly, AK; Illingworth, NA; Veal, GJ, 2011
)
2.08
"Fenretinide (4-HPR) is a cytotoxic retinoid with minimal systemic toxicity that has shown clinical activity against recurrent high-risk neuroblastoma. "( Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
DeClerck, YA; Fang, H; Harned, TM; Kalous, O; Maldonado, V; Reynolds, CP, 2011
)
2.12
"Fenretinide is an extremely hydrophobic chemopreventive compound with poor tissue permeability."( Mucoadhesive fenretinide patches for site-specific chemoprevention of oral cancer: enhancement of oral mucosal permeation of fenretinide by coincorporation of propylene glycol and menthol.
Desai, KG; Holpuch, AS; Mallery, SR; Phelps, MP; Schwendeman, SP; Wu, X, 2012
)
1.47
"Fenretinide is a synthetic retinoid that is being tested in clinical trials for the treatment of breast cancer and insulin resistance, but its mechanism of action has been elusive. "( Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis.
Bikman, BT; Fabriàs, G; Guan, Y; Holland, WL; Kim, JY; Shui, G; Siddique, MM; Summers, SA; Wenk, MR, 2012
)
3.26
"Fenretinide (4-HPR) is a synthetic retinoid that exhibits potent antitumor and chemopreventive activities against different malignancies, including ovarian tumors. "( AF1q: a novel mediator of basal and 4-HPR-induced apoptosis in ovarian cancer cells.
Appierto, V; Callari, M; Cavadini, E; Daidone, MG; Tiberio, P, 2012
)
1.82
"Fenretinide (4-HPR) is a synthetic retinoid that has shown clinical activity in recurrent NB and is cytotoxic to a variety of cancer cells, in part via the accumulation of dihydroceramides, which are precursors of GD2."( Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Huebener, N; Lee, DA; Lode, HN; Maurer, BJ; Reynolds, CP; Seidel, D; Shibina, A; Somanchi, SS; Stermann, A, 2013
)
2.55
"Fenretinide (4-HPR) is a retinoid analogue with antitumor and chemopreventive activities. "( Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Clifford, JL; Fischer, S; Kelloff, GJ; Lotan, R; Sabichi, AL; Steele, VE; Xu, H; Yang, X; Zou, C, 2003
)
1.99
"Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models."( Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
Baglietto, L; Decensi, A; Johansson, H; Mariette, F; Onetto, M; Paganuzzi, M; Serrano, D; Torrisi, R, 2005
)
2.05
"Fenretinide (4-HPR) is a synthetic retinoid that has been reported to inhibit the growth of cancer cell lines in vitro."( Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells.
Garcia, A; Golubkov, V; Markland, FS,
)
1.98
"Fenretinide is a semi-synthetic retinoid that has pro-apoptotic effects as a single agent and synergistically with chemotherapy in vitro. "( A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.
Chan, KK; Fischer, B; Grever, M; Lavelle, J; Otterson, GA; Shah, M; Villalona-Calero, MA; Wei, X, 2005
)
2.03
"Fenretinide (4-HPR) is a synthetic retinoid whose apoptosis-inducing effects have been demonstrated in many tumor types. "( BBC3 mediates fenretinide-induced cell death in neuroblastoma.
Cenacchi, N; Khan, J; Son, CG; Wei, JS; Whiteford, CC, 2005
)
2.13
"As fenretinide is a ceramide up-regulating drug that inhibits the activation of the pro-inflammatory transcriptional factor, nuclear factor (NF)-kappaB, the impact of fenretinide on unstimulated and tumor necrosis factor (TNF)-alpha stimulated production of NF-kappaB-dependent interleukin (IL)-8 was studied in immortalized wild-type (non-CF; 9HTEo-) and mutant DeltaF508 CFTR (CF; CFTE29o-) tracheal epithelial cells."( Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide.
Kubow, S; Lands, LC; Meehan, B; Vilela, RM, 2006
)
1.06
"Fenretinide is a synthetic retinoid with chemotherapeutic activity against various malignancies. "( Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers.
Jasti, B; Kokate, A; Li, X, 2007
)
2.05
"Fenretinide (4-HPR) is a synthetic retinoid with antitumor activity, which induces apoptosis in cancer cell lines of different histotypes. "( Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.
Appierto, V; Cavadini, E; Colombo, N; De Cecco, L; Formelli, F; Gariboldi, M; Lambert, JR; Pierotti, MA; Reid, J; Tiberio, P; Villani, MG, 2007
)
2.01
"Fenretinide (4-HPR) is a synthetic retinoid being clinically tested in the chemoprevention of different tumors and precancerous lesions. "( Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability.
Camerini, T; Campa, T; Costa, A; Crippa, A; De Palo, G; Del Vecchio, M; Delle Grottaglie, M; Di Mauro, MG; Formelli, F; Manzari, A; Mariani, L; Marubini, E; Veronesi, U,
)
1.85
"Fenretinide (4-HPR) is a synthetic retinoid that displays a broad range of biological effects and has also demonstrated clinical efficacy as a chemopreventative agent. "( Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation.
Darzynkiewicz, Z; DiPietrantonio, AM; Hsieh, TC; Juan, G; Traganos, F; Wu, JM, 2000
)
3.19
"Fenretinide is an effective inducer of apoptosis in many malignancies but its precise mechanism(s) of action in the induction of apoptosis in neuroblastoma is unclear. "( Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma.
Annichiarrico-Petruzzelli, M; Bernassola, F; Lovat, PE; Malcolm, AJ; Melino, G; Pearson, AD; Piacentini, M; Ranalli, M; Redfern, CP, 2000
)
2.06
"Fenretinide (4-HPR) is a synthetic retinoid with cancer chemopreventative potential and clinically manageable side effects, compared to the prototype retinoid, all-trans retinoic acid (RA). "( Apoptosis and restriction of G(1)/S cell cycle by fenretinide in Burkitt's lymphoma mutu I cell line accessed with bcl-6 down-regulation.
Hsieh, T; Wu, JM, 2000
)
2
"Fenretinide is a vitamin A derivative under investigation in cancer prevention trials. "( Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.
Arena, G; Baglietto, L; Decensi, A; Gonzaga, AG; Pasquetti, W; Robertson, C; Torrisi, R; Tosetti, F, 2000
)
2.08
"Fenretinide (HPR) is a synthetic retinoid which has been shown to cause a reduction in the incidence of carcinogen-induced epithelial tumors in experimental animals, and it has been chosen to be tested as a chemopreventive agent in humans. "( Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Buranelli, F; Campa, T; Carsana, R; Costa, A; Dossena, G; Formelli, F; Magni, A; Pizzichetta, M, 1989
)
1.96

Effects

Fenretinide has been used orally as a chemopreventive retinoid in a trial for women at risk of developing contralateral breast cancer. It has anti-tumor activity by acting on the actin cytoskeleton and by regulating FAK tyrosine phosphorylation.

ExcerptReferenceRelevance
"Fenretinide has been established to be cytotoxic to many kinds of cancer cells."( Fenretinide: a novel treatment for endometrial cancer.
Bulun, SE; Coon, JS; Dyson, M; Kim, JJ; Malpani, S; Mittal, N; Ono, M; Pavone, ME; Schink, JC, 2014
)
2.57
"Fenretinide has shown promise in the chemoprevention of breast cancer, a tumor type in which the oncogene cyclin D1 is overexpressed frequently. "( Cyclin d1 overexpression sensitizes breast cancer cells to fenretinide.
Germain, D; Hendley, J; O'Connell, MJ; Pirkmaier, A; Yuen, K, 2003
)
2
"Fenretinide has extensively been investigated because of its favorable toxicological profile in humans."( Breast cancer prevention trials using retinoids.
Bonanni, B; Cazzaniga, M; Decensi, A; Guerrieri-Gonzaga, A; Serrano, D, 2003
)
1.04
"Fenretinide has anti-tumor activity by acting on the actin cytoskeleton and by regulating FAK tyrosine phosphorylation. "( Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells.
Garcia, A; Golubkov, V; Markland, FS,
)
1.98
"Fenretinide has been examined in clinical trials as a cancer chemopreventive and chemotherapeutic agent."( Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines.
Horinaka, M; Kouhara, J; Nakata, S; Sakai, T; Ueda, Y; Wakada, M; Yamagishi, H; Yoshida, T, 2007
)
2.5
"Fenretinide has been used orally as a chemopreventive retinoid in a trial for women at risk of developing contralateral breast cancer. "( Distribution of fenretinide in the mammary gland of breast cancer patients.
Costa, A; Formelli, F; Hawthorne, M; Mehta, RG; Moon, RC, 1991
)
2.07

Actions

Fenretinide did not increase free arachidonic acid levels, but increased LOX activity without a detectable increase in 12-LOX protein. The fen retinide-induced increase in photoreceptor cell markers, accompanied by a decrease in RPE cell markers suggests that retinoids may play a role in the transdifferentiation of RPE cells.

ExcerptReferenceRelevance
"Fenretinide did not increase DR expression in non-malignant cells."( Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours.
Burchill, SA; White, DE, 2010
)
2.52
"The fenretinide-induced increase in photoreceptor cell markers, accompanied by a decrease in RPE cell markers, suggests that retinoids may play a role in the transdifferentiation of RPE cells."( The expression of retinal cell markers in human retinal pigment epithelial cells and their augmentation by the synthetic retinoid fenretinide.
Carr, AJ; Coffey, P; Greenwood, J; Moss, SE; Semo, M; Vugler, AA; Yu, L, 2011
)
1.05
"Fenretinide did not increase free arachidonic acid levels, but increased LOX activity without a detectable increase in 12-LOX protein."( GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma.
Aughton, K; Bernassola, F; Corazzari, M; Hewson, QD; Lovat, PE; Maccarrone, M; Melino, G; Oliverio, S; Pearson, AD; Piacentini, M; Ranalli, M; Redfern, CP; Rodolfo, C, 2002
)
1.31

Treatment

Fenretinide treatment significantly lowered body weight, glucose levels and plasma levels of total cholesterol, triglycerides, and phospholipids. Fenret inide-treated cells also demonstrated F-actin disruption, significant inhibition of both directed migration and invasion of a synthetic basement membrane, and decreased phosphorylation of growth-promoting kinases.

ExcerptReferenceRelevance
"Fenretinide treatment significantly lowered body weight, glucose levels and plasma levels of total cholesterol, triglycerides, and phospholipids. "( Fenretinide treatment accelerates atherosclerosis development in apoE-deficient mice in spite of beneficial metabolic effects.
Amadio, P; Arnaboldi, F; Barbieri, SS; Bonacina, F; Busnelli, M; Chiesa, G; Donetti, E; Laaksonen, R; Manzini, S; Paltrinieri, S; Sandrini, L; Scanziani, E; Soldati, S, 2020
)
3.44
"Fenretinide-treated cells also demonstrated F-actin disruption, significant inhibition of both directed migration and invasion of a synthetic basement membrane, and decreased phosphorylation of growth-promoting kinases."( Fenretinide Perturbs Focal Adhesion Kinase in Premalignant and Malignant Human Oral Keratinocytes. Fenretinide's Chemopreventive Mechanisms Include ECM Interactions.
Border, MB; Han, BB; Holpuch, AS; Li, S; Liu, Z; Mallery, SR; Pei, P; Sarode, S; Schwendeman, SP; Spinney, R; Tong, M; Wang, D, 2015
)
2.58
"Fenretinide treatment deactivated ERK1/2 in Huh7 cells, but activated ERK1/2 in HepG2 cells, which was positively associated with the sensitivity of cells to the apoptotic effect of fenretinide."( ERK1/2 deactivation enhances cytoplasmic Nur77 expression level and improves the apoptotic effect of fenretinide in human liver cancer cells.
Li, Y; Nie, Y; Wan, YJ; Yang, H, 2011
)
1.31
"Upon fenretinide and HDACi treatment, the expression of RARβ and Nur77 were induced and colocalized in the cytosol."( Enrichment of Nur77 mediated by retinoic acid receptor β leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors.
Wan, YJ; Yang, H; Zhan, Q, 2011
)
1.03
"All fenretinide-treated tissues showed significantly increased intraepithelial apoptosis (TUNEL) positivity, implying activation of intersecting apoptotic and differentiation pathways."( Evaluation of a mucoadhesive fenretinide patch for local intraoral delivery: a strategy to reintroduce fenretinide for oral cancer chemoprevention.
Border, MB; Chen, W; Desai, KG; Fields, HW; Han, BB; Holpuch, AS; Koutras, GM; Larsen, PE; Liu, Z; Mallery, SR; Pei, P; Phelps, MP; Schwendeman, SP; Seghi, GA; Stoner, GD; Tong, M; Warner, BM, 2012
)
1.15
"Fenretinide treatment produced dose-dependent reversible reductions in serum RBP-retinol that were associated with trends in reduced lesion growth rates. "( Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration.
Bui, TV; Han, Y; Lichter, JB; Mata, NL; Singerman, LJ; Vogel, R, 2013
)
2.15
"Fenretinide treatment also increased levels of the death receptor DR5 and caused mitochondrial membrane depolarization."( Induction of apoptosis in primary meningioma cultures by fenretinide.
Chen, L; Li, JT; McCutcheon, IE; Puduvalli, VK, 2005
)
1.3
"Fenretinide treatment had no significant effect on cancer progression and death."( Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer.
Branchi, D; Bruno, S; Bruzzi, P; Curotto, A; Decensi, A; Puntoni, M; Varaldo, M; Zanardi, S, 2007
)
1.06
"Fenretinide treatment took place over 1 year with a regimen of 100 mg/day for 25 days with 3 day hiatus intervals."( Electroretinographic findings in subjects after administration of fenretinide.
Esper, P; Krzeminski, R; Pienta, K; Zwas, F,
)
1.09
"Fenretinide treatment resulted in cleavage of poly ADP-ribose polymerase, indicating an activation of the caspase 3."( Fenretinide activates caspases and induces apoptosis in gliomas.
Kouraklis, GP; Kyritsis, AP; Levin, VA; Puduvalli, VK; Saito, Y; Xu, R, 1999
)
2.47
"Fenretinide treatment of women with breast cancer for 5 years appears to have no statistically significant effect on the incidence of second breast malignancies overall, although a possible benefit was detected in premenopausal women. "( Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Boni, C; Camerini, T; Campa, T; Costa, A; D'Aiuto, G; De Palo, G; Decensi, A; Del Turco, MR; Del Vecchio, M; Di Mauro, MG; Formelli, F; Magni, A; Malone, WF; Mariani, L; Marubini, E; Miceli, R; Muraca, MG; Perloff, M; Pinto, C; Sporn, MB; Veronesi, U, 1999
)
2.07
"Fenretinide treatment was associated with a lower incidence of ovarian carcinoma during the intervention period but such a protective effect seems to disappear after treatment. "( Effect of fenretinide on ovarian carcinoma occurrence.
Camerini, T; De Palo, G; Decensi, A; Formelli, F; Mariani, L; Marubini, E; Pasini, B; Veronesi, U, 2002
)
2.16
"Treatment with fenretinide decreases the levels of long-chain ceramides and increases the levels of very long-chain ceramides."( Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside.
Abu-Arish, A; Cupri, S; De Sanctis, JB; Garić, D; Hajduch, M; Hanrahan, JW; Houle, D; Matouk, E; Radzioch, D; Wojewodka, G, 2017
)
2.24
"Treatment with fenretinide significantly decreased total cell count (doses 5-20 µL) and viability (doses 10-20 µmol/L). "( Fenretinide: A Potential Treatment for Endometriosis.
Bulun, SE; Dyson, M; Kim, JJ; Malpani, SS; Pavone, ME, 2016
)
2.23
"Treatment with fenretinide (N-(4-hydroxyphenyl)retinamide; 4-HPR) normalized high levels of AA and low levels of ceramide, and increased the levels of DHA in CF mice."( Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide.
De Sanctis, JB; Guilbault, C; Hajduch, M; Matouk, E; Radzioch, D; Saeed, Z; Wojewodka, G, 2009
)
0.92
"Cotreatment with fenretinide and DR ligands resulted in synergistic death compared with either agent alone; caspase-8 and Bid were cleaved in a time-dependent manner."( Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours.
Burchill, SA; White, DE, 2010
)
2.13
"Treatment with fenretinide for 7 days induced the formation of neuronal-like processes in ARPE-19 cells. "( The expression of retinal cell markers in human retinal pigment epithelial cells and their augmentation by the synthetic retinoid fenretinide.
Carr, AJ; Coffey, P; Greenwood, J; Moss, SE; Semo, M; Vugler, AA; Yu, L, 2011
)
0.93

Toxicity

The combination of low-dose tamoxifen and fenretinide is safe but not synergistic in lowering IGF-I levels in premenopausal women.

ExcerptReferenceRelevance
" Based on the lethality data, all-trans-retinoic acid was most toxic followed by all-trans-HER greater than all-trans-HPR greater than all-trans-ER."( Subacute toxicity of all-trans- and 13-cis-isomers of N-ethyl retinamide, N-2-hydroxyethyl retinamide, and N-4-hydroxyphenyl retinamide.
Meeks, RG; Sani, BP, 1983
)
0.27
" These results emphasize the need for pilot toxicity studies, especially when components of the test system are varied, to assess the effect of drug concentration on the toxic response."( Alterations of drug-induced toxicity in the mouse lymphoma assay by a rat hepatic microsomal metabolizing system (S-9).
Oldham, JW; Paulson, JD; Preston, RF; Pritchard, JF, 1984
)
0.27
" The 4-HPR and safingol combination was cytotoxic in low-oxygen conditions and was minimally toxic to normal fibroblasts and bone marrow myeloid progenitor cells."( Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.
Billups, C; Cabot, MC; Maurer, BJ; Melton, L; Reynolds, CP, 2000
)
0.31
"To describe the pattern of occurrence of adverse events commonly arising during treatment with fenretinide, a synthetic retinoid under investigation for cancer prevention."( Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
Camerini, T; Costa, A; De Palo, G; Decensi, A; Di Mauro, MG; Mariani, L; Marubini, E; Veronesi, U, 2001
)
0.81
"The most common adverse events were diminished dark adaptation (cumulative incidence, 19."( Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
Camerini, T; Costa, A; De Palo, G; Decensi, A; Di Mauro, MG; Mariani, L; Marubini, E; Veronesi, U, 2001
)
0.59
" Thirty-six patients have dropped out of the study, 17 because of adverse events and 19 for various other reasons."( Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
Bonanni, B; Cazzaniga, M; Decensi, A; Formelli, F; Franchi, D; Guerrieri-Gonzaga, A; Gulisano, M; Intra, M; Johansson, H; Johnson, K; Latronico, A; Mora, S; Pelosi, G; Robertson, C; Serrano, D, 2006
)
0.54
"The combination of low-dose tamoxifen and fenretinide is safe but not synergistic in lowering IGF-I levels in premenopausal women."( Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
Bonanni, B; Cazzaniga, M; Decensi, A; Formelli, F; Franchi, D; Guerrieri-Gonzaga, A; Gulisano, M; Intra, M; Johansson, H; Johnson, K; Latronico, A; Mora, S; Pelosi, G; Robertson, C; Serrano, D, 2006
)
0.81
"In contrast to the expected additive/synergistic effect on cell growth inhibition, the sub-toxic and toxic concentrations of 4-HPR protected GM3 treated cells."( Inhibitors of EGFR signaling retard cytotoxicity of fenretinide in rat gliosarcoma cells.
Sahu, SK; Traynelis, VC; Zaheer, A, 2008
)
0.6
" acute toxicity test for assessing the adverse effects of chemicals on aquatic invertebrates stipulates the use of neonates that are ≤24 h old (hours post release [hpr]) at the start of the exposure."( Age and Synchronization of Daphnia magna Affect Sensitivity to Teflubenzuron in Acute Standardized Toxicity Tests.
Rundberget, JT; Schmid, S; Song, Y; Tollefsen, KE, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" Initial estimates of plasma pharmacokinetic parameters after oral administration of 4HPR (300 mg/day) [corrected] in 3 cancer patients were the following: 4HPR, t beta 1/2 = 13."( Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients.
Alberts, DS; Dalton, WS; Lim, H; Meyskens, FL; Peng, YM; Xu, MJ, 1989
)
0.28
" The apparent volume of distribution of HPR was approximately 10-12 liter/kg and the terminal half-life was 12 hr."( Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats.
Sporn, MB; Swanson, BN; Zaharevitz, DW,
)
0.13
" All-trans retinoic acid permeated well into the WM, giving peak concentration in WM of 25."( Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat.
Albessard, F; Barre, L; Debruyne, D; Defer, GL; Le Doze, F, 2000
)
0.54
" Pharmacokinetic sampling was performed on days 1 and 28 of the first course."( Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
Bellani, FF; Boni, L; Cavadini, E; De Bernardi, B; Decensi, A; Formelli, F; Garaventa, A; Lo Piccolo, MS; Luksch, R; Montaldo, PG; Pizzitola, MR; Ponzoni, M, 2003
)
0.59
" 4HPR half-life increased from 17 h after the first administration to 25 h after the 28(th) administration."( Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
Bellani, FF; Boni, L; Cavadini, E; De Bernardi, B; Decensi, A; Formelli, F; Garaventa, A; Lo Piccolo, MS; Luksch, R; Montaldo, PG; Pizzitola, MR; Ponzoni, M, 2003
)
0.59
" PK analysis demonstrated a reduction in fenretinide Cmax on day 8 compared to day 2, accompanying a decrease in AUC."( A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.
Chan, KK; Fischer, B; Grever, M; Lavelle, J; Otterson, GA; Shah, M; Villalona-Calero, MA; Wei, X, 2005
)
0.85
" Quantitative system pharmacodynamic models could promote the discovery and development of combination regimens based upon first principles."( Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics.
Harrold, JM; Mager, DE; Straubinger, RM, 2012
)
0.38
" The validated method was successfully applied to the analyses of the pharmacokinetic study for patients treated with 4-HPR in a clinical trial."( Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics.
Cho, HE; Min, HK, 2017
)
0.83

Compound-Compound Interactions

ExcerptReferenceRelevance
" On the basis of these proposed mechanisms, retinoids that do not cause differentiation as sole agents may have utility in the clinic in combination with RA."( N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
Breitman, TR; Sausville, EA; Takahashi, N, 1995
)
0.58
" We performed this study to determine the toxicity of cisplatin, paclitaxel and fenretinide in patients with advanced cancer, the recommended phase II dose of these agents together, and the pharmacokinetics (PK) of fenretinide when administered with chemotherapy."( A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.
Chan, KK; Fischer, B; Grever, M; Lavelle, J; Otterson, GA; Shah, M; Villalona-Calero, MA; Wei, X, 2005
)
0.81
" With 10 μM 13cRA, less than 50% of cells survived when combined with various concentrations of CEP-701."( Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.
Adamson, PC; Brodeur, GM; Maris, JM; Minturn, JE; Norris, RE, 2011
)
0.37
" Our data support clinical evaluation of 4-HPR combined with ABT-751 in recurrent and refractory neuroblastoma."( Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.
Chen, NE; Khankaldyyan, V; Maldonado, NV; Maurer, BJ; Reynolds, CP; Shimada, H; Song, MM, 2016
)
0.68
" Our work was aim to prepare N-(4-hydroxyphenyl) retinamide-loaded lipid microbubbles (4HPR-LM) combined with ultrasound for anti-keloid therapy."( Lipid nano-bubble combined with ultrasound for anti-keloids therapy.
Gao, Z; Jin, HY; Jin, ZH; Li, ZN; Wang, QM; Wang, XQ, 2018
)
0.48
" Because cancer cells appear to be more susceptible to increased levels of the endoplasmic reticulum (ER) stress than normal cells, herein we tested the hypothesis that FoscanPDT combined with HPR or LCL29 induces FB-sensitive ER stress-associated apoptosis that affects cell survival."( Fumonisin B1 Inhibits Endoplasmic Reticulum Stress Associated-apoptosis After FoscanPDT Combined with C6-Pyridinium Ceramide or Fenretinide.
Bielawska, A; Bielawski, J; Boppana, NB; Delor, JS; Korbelik, M; Kraveka, JM; Li, LI; Pierce, JS; Rahmaniyan, M; Separovic, D; Zhang, K, 2017
)
0.66

Bioavailability

Fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) has shown promising anticancer activity in preclinical studies, but its limited oral bioavailability has hindered clinical assessment. Low bioavailability may have limited fen retinide activity.

ExcerptReferenceRelevance
"The effects of meals and meal composition on the bioavailability of fenretinide, N-(4-hydroxyphenyl) retinamide, a synthetic retinoid undergoing clinical trials, were examined in two separate studies using an open, randomized, crossover design."( Effects of meals and meal composition on the bioavailability of fenretinide.
Doose, DR; Minn, FL; Nayak, RK; Stellar, S, 1992
)
0.76
" As a result of this dual effect, the bioavailability of IGF-1 for interaction with receptors at target levels further decreased in pre-menopausal 4-HPR treated patients compared with controls, suggesting that retinoid administration may result in lower concentrations of biologically active IGF-1."( Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.
Barreca, A; Casella, C; Costa, A; De Palo, G; Decensi, A; Fontana, V; Parodi, S; Pensa, F; Torrisi, R, 1998
)
0.7
" This method can be used to quantify 4-HPR and 4-MPR in different tissues to determine the bioavailability of 4-HPR."( Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues.
Frgala, T; Maurer, BJ; Patrick Reynolds, C; Vratilova, J, 2004
)
0.32
"Fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)] is a cytotoxic retinoid that suffers from a wide interpatient variation in bioavailability when delivered orally in a corn oil capsule."( Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Burgess, SW; Frgala, T; Janeba, J; Kalous, O; Khankaldyyan, V; Maldonado, V; Maurer, BJ; McKee, RT; Reynolds, CP; Shaw, WA; Sun, BC; Wu, X; Yesair, DW, 2007
)
1.78
" The main reason is that the drug's hydrophobicity hinders its bioavailability in the body fluids."( Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration.
Bergamante, V; Carosio, R; Cilli, M; Gotti, R; Montaldo, PG; Orienti, I; Zuccari, G, 2007
)
1.78
" Thus, betaLG may show benefits in improving the bioavailability of retinoid derivatives."( The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
Heikura, JM; Pohjala, LL; Riihimäki-Lampén, LH; Vahermo, M; Vainio, MJ; Valkonen, KH; Virtanen, VT; Vuorela, PM; Yli-Kauhaluoma, JT, 2010
)
0.36
" Low bioavailability of 4-HPR has been limiting its therapeutic applications."( Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure.
Cooper, JP; Curley, RW; Hwang, K; Kang, MH; Maurer, BJ; Reynolds, CP; Singh, H; Wang, D; Williams, SC, 2011
)
1.81
"The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) has shown promising anticancer activity in preclinical studies, but its limited oral bioavailability has hindered clinical assessment."( Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.
Crandon, S; Doroshow, JH; Gutierrez, ME; Kang, M; Kummar, S; Maurer, BJ; Murgo, AJ; Reynolds, CP; Singh, H, 2011
)
1.02
" Low bioavailability may have limited fenretinide activity."( Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
Ames, MM; Buhrow, SA; Cohn, SL; Jackson, H; Kitchen, BJ; London, WB; McGovern, RM; McGrady, P; Naranjo, A; Parisi, MT; Reid, JM; Reynolds, CP; Shulkin, B; Sondel, PM; Stranzinger, E; Villablanca, JG; Yanik, GA, 2011
)
0.88
"The major limitation to successful chemotherapy of neuroblastoma (NB) is the toxicity and the poor bioavailability of traditional drugs."( Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration.
Carosio, R; Cavadini, E; Emionite, L; Formelli, F; Mangraviti, S; Montaldo, PG; Ognio, E; Orienti, I; Pistoia, V; Zuccari, G, 2012
)
0.64
" In clinical trials, fenretinide has shown poor therapeutic efficacy following oral administration - attributed to its low bioavailability and solubility."( Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles.
Bostanian, LA; Glotser, EY; Graves, RA; Ledet, GA; Mandal, TK, 2015
)
0.99
" Despite substantial in vitro cytotoxicity, response rates in early clinical trials with 4-HPR have been less than anticipated, likely due to the low bioavailability of the initial oral capsule formulation."( Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cho, H; Cooper, JP; Kang, MH; Reynolds, CP, 2017
)
0.76
"Fenretinide is a synthetic retinoid characterized by anticancer activity in preclinical models and favorable toxicological profile, but also by a low bioavailability that hindered its clinical efficacy in former clinical trials."( A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors.
Baiocchi, M; Boe, A; Bongiorno-Borbone, L; Bruselles, A; Contavalli, P; Costantino, A; De Angelis, ML; De Maria, R; Eramo, A; Fecchi, K; Francescangeli, F; Giuliani, A; Kitamura, T; La Torre, F; Melino, G; Oki, T; Orienti, I; Peschiaroli, A; Salvati, V; Sette, G; Signore, M; Spada, M; Tartaglia, M; Zeuner, A; Zolla, L, 2019
)
2.29
"Here, we developed a novel nano-micellar fenretinide formulation called bionanofenretinide (Bio-nFeR), based on drug encapsulation in an ion-pair stabilized lipid matrix, with the aim to raise fenretinide bioavailability and antitumour efficacy."( A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells.
Baiocchi, M; Bello, E; Bongiorno-Borbone, L; De Angelis, ML; De Maria, R; Di Virgilio, A; Eramo, A; Falchi, M; Ferrari, M; Francescangeli, F; Matteo, C; Melino, G; Orienti, I; Peschiaroli, A; Salvati, V; Sette, G; Zeuner, A; Zolla, L; Zucchetti, M, 2019
)
1.09
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" New nanomicelles were prepared as carriers for this combination to maximize bioavailability and accumulation at the tumor site because of the enhanced permeability and retention (EPR) effect."( A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model.
Brodeur, GM; Calonghi, N; Chorny, M; Farruggia, G; Guan, P; Kolla, V; Nguyen, F; Orienti, I, 2019
)
0.79
" Biodegradable polymeric implants formulated to preserve 4HPR's function and bioavailability were employed to assess 4HPR's chemopreventive impact on an OSCC tumor induction model."( Fenretinide combines perturbation of signaling kinases, cell-extracellular matrix interactions and matrix metalloproteinase activation to inhibit invasion in oral squamous cell carcinoma cells.
Bissonnette, C; Din, C; Lin, YX; Liu, Y; Mallery, SR; Nieto, K; Pei, P; Schwendeman, SP; Shea, FF; Spinney, R; Wang, D, 2022
)
2.16

Dosage Studied

Fenretinide was inactive against recurrent malignant gliomas at the dosage used in this trial. This combination may have activity in a variety of tumors. The number of pills required complicates oral dosing and limits the applicability of this regimen.

ExcerptRelevanceReference
" In mice dosed with 10 mg/kg 4-HPR, the parent compound, MPR, a putative 4-HPR ester, and three of the MPR metabolites (7, 13, and 18 min) were found."( Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice.
Filla, MS; Hultin, TA; McCormick, DL,
)
0.13
" The mean plasma retinol concentrations for 9 patients decreased 60% from baseline to below 200 ng/ml within 1-2 weeks of 4HPR dosing initiation."( Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients.
Alberts, DS; Dalton, WS; Lim, H; Meyskens, FL; Peng, YM; Xu, MJ, 1989
)
0.28
" A 5-day ip dosing study (5 mg/kg/day of 4-HPR) in both rats and mice revealed that 4-HPR distributed to all tissues examined with the highest levels reached in the urinary bladder."( N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice.
Hultin, TA; May, CM; Moon, RC,
)
0.13
" A dose-dependent and statistically significant reduction in maternal plasma retinol levels was observed across all dosage groups."( Teratogenicity of N-(4-hydroxyphenyl)-all-trans-retinamide in rats and rabbits.
Kenel, MF; Krayer, JH; Merz, EA; Pritchard, JF, 1988
)
0.27
" Dosage was either 1 or 2 mmol 4-HPR/kg of chow."( Dose-dependent suppression by the synthetic retinoid, 4-hydroxyphenyl retinamide, of streptococcal cell wall-induced arthritis in rats.
Allen, JB; Brinckerhoff, CE; Haraoui, B; Helfgott, RK; Sporn, MB; Wilder, RL, 1985
)
0.27
" Experimental and control groups were sacrificed at various time points between 5 and 11 months after dosing with N-nitroso-N-methylurea in order to visualize progressive stages of carcinogenesis of the dorsolateral prostate, the anterior prostate, and the seminal vesicle."( Histogenesis of induced prostate and seminal vesicle carcinoma in Lobund-Wistar rats: a system for histological scoring and grading.
Anzano, MA; Kadomatsu, K; Slayter, MV; Smith, JM; Sporn, MB, 1994
)
0.29
" Oltipraz was fed in the diet from one week prior to OH-BBN dosing until sacrifice, six months later."( Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO.
Detrisac, CJ; Kelloff, GJ; Moon, RC; Sigman, CC; Steele, VE; Thomas, CF,
)
0.13
" Dose-response studies suggest that like retinoids, glucarate acts directly on tumor cells, rather than having an adjuvant effect."( Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination.
Abou-Issa, H; Curley, RC; Nguyen, MH; Stromberg, PC; Webb, TE,
)
0.13
" With the daily dosage of 200 mg and after follow-up, no changes in mammographic patterns were observed."( Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR).
Cassano, E; Coopmans de Yoldi, G; Costa, A; De Palo, G; Ferranti, C; Mascotti, G; Veronesi, U, 1993
)
0.53
"No beneficial clinical effect was observed with the retinoid 4-HPR in the treatment of severe, longstanding RA at the 300 mg/day dosage studied."( N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study.
Anderson, RJ; Coblyn, J; Formelli, F; Gravallese, EM; Handel, ML; Karlson, EW; Maier, A; Ruderman, EM; Sperling, RI; Weinblatt, ME, 1996
)
0.29
" These encouraging preliminary results suggest the need for further studies to evaluate the best dosage schedules and duration of 4-HPR topical application in actinic keratoses."( Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses.
Accetturi, M; Baliva, G; Bono, A; De Palo, G; Formelli, F; Moglia, D; Nava, M, 1996
)
0.57
" Unlike the demonstrated prevention of colon cancer by the other two retinoids, both dosing schedules of 2-CPR resulted in an approximate doubling of the yield of colon tumors."( Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci.
Kelloff, GJ; Kramer, PM; Lubet, RA; Pereira, MA; Steele, VE; Zheng, Y, 1999
)
0.3
" One patient with AG treated at 900 mg/m(2) bid dosage had a partial radiologic response."( Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
Chang, SM; Cloughesy, TF; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Junck, L; Kuhn, JG; Levin, VA; Lieberman, F; Liu, V; Mehta, MP; Meyers, CA; Nicholas, MK; Prados, M; Puduvalli, VK; Wen, P; Yung, WK; Zwiebel, J, 2004
)
0.66
"Fenretinide was inactive against recurrent malignant gliomas at the dosage used in this trial."( Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
Chang, SM; Cloughesy, TF; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Junck, L; Kuhn, JG; Levin, VA; Lieberman, F; Liu, V; Mehta, MP; Meyers, CA; Nicholas, MK; Prados, M; Puduvalli, VK; Wen, P; Yung, WK; Zwiebel, J, 2004
)
2.1
" This combination may have activity in a variety of tumors, however, the number of pills required complicates oral dosing of fenretinide, and limits the applicability of this regimen."( A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.
Chan, KK; Fischer, B; Grever, M; Lavelle, J; Otterson, GA; Shah, M; Villalona-Calero, MA; Wei, X, 2005
)
0.79
"Classical isobologram analysis offers a way for analysing combined drug effects in dose-response experiments statistically."( Statistical analysis of combined dose effects for experiments with two agents.
Lehmer, A; Treiber, U; Wagenpfeil, S, 2006
)
0.33
"Our package supplements the clinical software-equipment and is a tool for automatic evaluation of combined dose-response experiments in experimental oncology in the urologic clinic."( Statistical analysis of combined dose effects for experiments with two agents.
Lehmer, A; Treiber, U; Wagenpfeil, S, 2006
)
0.33
"To determine the maximal tolerated dosage (MTD) of oral fenretinide given as intact capsules for 7 days, repeated every 21 days, in children with high-risk solid tumors."( Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
Ames, MM; Krailo, MD; Reaman, GH; Reid, JM; Reynolds, CP; Reynolds, PC; Villablanca, JG, 2006
)
0.89
" Cytotoxicity of deferoxamine for neuroblastoma cell lines measured by the DIMSCAN assay achieved dose-response curves similar to data obtained by manual trypan blue counts or colony formation in soft agar but with a wider dynamic range."( A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.
Frgala, T; Kalous, O; Proffitt, RT; Reynolds, CP, 2007
)
0.34
"4-5 microM for 4-HPR and 4-oxo-4-HPR, respectively) were maintained during the 24 h dosing interval in the dose range 300-4,000 mg/m(2)."( Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
Appierto, V; Cavadini, E; Formelli, F; Garaventa, A; Luksch, R; Persiani, S; Villani, MG, 2008
)
0.65
" From our results, we expected that the using of fenretinide in combination with cisplatin or paclitaxel can possibly lower the dosage of these drugs."( Synergistic growth-inhibitory effects of fenretinide with either cisplatin or paclitaxel on human epithelial ovarian cancer cell line (SKOV-3).
Chicharoen, S; ImAim, C; Liabsuetrakul, T; Reungrairatanaroj, P, 2004
)
0.84
"The findings of this study and the established safety profile of fenretinide in chronic dosing regimens warrant further study of fenretinide in the treatment of geographic atrophy."( Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration.
Bui, TV; Han, Y; Lichter, JB; Mata, NL; Singerman, LJ; Vogel, R, 2013
)
0.94
" A1120 dosing in mice induced 75% reduction in serum RBP4, which correlated with reduction in visual cycle retinoids and ocular levels of lipofuscin fluorophores."( A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis.
Allikmets, R; Dobri, N; Kong, J; Liu, Z; Ma, JX; Moiseyev, G; Petrukhin, K; Qin, Q; Sparrow, JR; Yamamoto, K, 2013
)
0.39
" Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase."( Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens.
Chung, HK; Lamb, K; Lin, MZ; Plemper, RK; Weisshaar, M; Yan, D, 2015
)
0.42
" Two sustained release formulations, one incorporating 20% Brij 98 and the other incorporating 3% MgCO3 in the oil phase, were selected for dosing in Sprague-Dawley rats and compared to a single injection of an equivalent dose of fenretinide drug suspension."( Design of Controlled Release PLGA Microspheres for Hydrophobic Fenretinide.
Mitra, A; Mittal, S; Schwendeman, SP; Wischke, C; Zhang, Y, 2016
)
0.86
" We have now determined the effects of concurrent ketoconazole on 4-HPR cytotoxic dose-response in four neuroblastoma (NB) cell lines in vitro and on 4-HPR activity against two cell line-derived, subcutaneous NB xenografts (CDX) and three patient-derived NB xenografts (PDX)."( P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
Kang, MH; Lopez-Barcons, L; Maurer, BJ; Reynolds, CP, 2017
)
0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
retinoidOxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (148)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.39810.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency25.73660.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency50.11870.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency19.95260.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency24.64405.623417.292931.6228AID2323; AID485281
Chain A, CruzipainTrypanosoma cruziPotency15.84890.002014.677939.8107AID1476
acid sphingomyelinaseHomo sapiens (human)Potency100.000014.125424.061339.8107AID504937
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
acetylcholinesteraseHomo sapiens (human)Potency17.23600.002541.796015,848.9004AID1347397; AID1347398
glp-1 receptor, partialHomo sapiens (human)Potency10.06630.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency31.28670.100020.879379.4328AID488772; AID488773; AID588453; AID588456
BRCA1Homo sapiens (human)Potency5.62340.89137.722525.1189AID624202
15-lipoxygenase, partialHomo sapiens (human)Potency10.00000.012610.691788.5700AID887
pregnane X receptorRattus norvegicus (Norway rat)Potency44.66840.025127.9203501.1870AID651751
phosphopantetheinyl transferaseBacillus subtilisPotency89.12510.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency29.58803.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency13.50010.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency26.83250.173734.304761.8120AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency27.49980.004110.890331.5287AID493107; AID504467
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency33.99720.031637.5844354.8130AID504865; AID743255
NFKB1 protein, partialHomo sapiens (human)Potency6.30960.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624146
PPM1D proteinHomo sapiens (human)Potency32.99930.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency26.83250.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency11.69060.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency18.72640.000714.592883.7951AID1259368; AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency17.80300.180013.557439.8107AID1460
ThrombopoietinHomo sapiens (human)Potency10.00000.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency29.87800.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency18.24070.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency50.09320.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency18.86770.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency39.81070.00137.762544.6684AID2120
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency45.60170.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency44.09410.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency33.43350.000417.946075.1148AID1346784; AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency13.72740.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.76190.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency63.09570.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency30.45330.000214.376460.0339AID588532; AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency13.71070.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency32.88280.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.27630.001530.607315,848.9004AID1224819; AID1224820; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency41.24020.375827.485161.6524AID588526; AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency26.65760.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.15980.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency2.75400.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency24.54540.00108.379861.1304AID1645840
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency14.50150.00018.4406100.0000AID720579; AID720580
glucocerebrosidaseHomo sapiens (human)Potency15.84890.01268.156944.6684AID2101
ParkinHomo sapiens (human)Potency29.09290.819914.830644.6684AID720573
P53Homo sapiens (human)Potency79.43280.07319.685831.6228AID504706
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency37.88200.001024.504861.6448AID588535; AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency39.68750.001019.414170.9645AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency28.52370.023723.228263.5986AID588541; AID743222; AID743223
caspase-3Homo sapiens (human)Potency50.09320.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency17.58860.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency12.58930.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency44.66840.016525.307841.3999AID602332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency20.66740.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency29.41650.001628.015177.1139AID1224843; AID1224895; AID1259385
activating transcription factor 6Homo sapiens (human)Potency34.90860.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency40.141819.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency25.69040.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency35.48130.10009.191631.6228AID1346983
Caspase-7Cricetulus griseus (Chinese hamster)Potency51.91430.006723.496068.5896AID1346980
Bloom syndrome protein isoform 1Homo sapiens (human)Potency28.18380.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency20.48390.316212.443531.6228AID902; AID924
D(1A) dopamine receptorHomo sapiens (human)Potency5.42620.02245.944922.3872AID488982; AID488983
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency32.46480.006026.168889.1251AID488953; AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency44.96470.010039.53711,122.0200AID588545; AID588547
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency22.14270.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
caspase-3Cricetulus griseus (Chinese hamster)Potency51.91430.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency7.17090.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency22.39010.037617.082361.1927AID1259364; AID1259388
heat shock protein beta-1Homo sapiens (human)Potency35.59900.042027.378961.6448AID743210; AID743228
huntingtin isoform 2Homo sapiens (human)Potency19.95260.000618.41981,122.0200AID1688
importin subunit beta-1 isoform 1Homo sapiens (human)Potency14.12545.804836.130665.1308AID540263
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID1454
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency39.81074.466824.832944.6684AID651749
flap endonuclease 1Homo sapiens (human)Potency18.52060.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency91.99970.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency17.83670.00378.618923.2809AID2660; AID2666; AID2667; AID2668
snurportin-1Homo sapiens (human)Potency14.12545.804836.130665.1308AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency42.26210.000627.21521,122.0200AID651741; AID720636; AID743202
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.68570.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency22.50570.004611.374133.4983AID463097; AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency7.63250.005612.367736.1254AID624032; AID624044
survival motor neuron protein isoform dHomo sapiens (human)Potency12.58930.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency0.89130.177824.735279.4328AID488949
lethal factor (plasmid)Bacillus anthracis str. A2012Potency10.00000.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency16.27100.891312.067628.1838AID1459; AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency20.66740.001557.789015,848.9004AID1259244
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency56.23416.309660.2008112.2020AID720707
Glycoprotein hormones alpha chainHomo sapiens (human)Potency15.84894.46688.344810.0000AID624291
Interferon betaHomo sapiens (human)Potency25.43800.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency2.75400.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency48.03890.002319.595674.0614AID651631; AID651743; AID720552
Integrin beta-3Homo sapiens (human)Potency25.11890.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency25.11890.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency20.66740.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
D(1A) dopamine receptorSus scrofa (pig)Potency13.09180.00378.108123.2809AID2667
Nuclear receptor ROR-gammaHomo sapiens (human)Potency26.60320.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency8.91251.995325.532750.1187AID624287
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency2.75400.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency26.37040.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency24.38540.011912.222168.7989AID588378; AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency2.75400.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Retinoic acid receptor gamma Homo sapiens (human)Ki0.40000.00001.997510.0000AID199055
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki2.20000.00010.949010.0000AID35839
Alpha-1A adrenergic receptorBos taurus (cattle)Ki2.20000.00000.50723.7020AID35839
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki2.80000.00010.739610.0000AID41913
Retinoic acid receptor RXR-alphaHomo sapiens (human)Ki2.20000.00040.56927.6320AID35839
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki2.20000.00000.575110.0000AID35839
Retinoic acid receptor RXR-betaHomo sapiens (human)Ki2.80000.00050.15920.8810AID41913
Indoleamine 2,3-dioxygenase 1Mus musculus (house mouse)IC50 (µMol)59.90000.00601.625110.0000AID717846
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki2.20000.00000.965010.0000AID35839
Retinoic acid receptor RXR-gammaHomo sapiens (human)Ki6.00000.00140.15261.0000AID73356
Indoleamine 2,3-dioxygenase 2Mus musculus (house mouse)IC50 (µMol)18.70001.50005.08758.2000AID717845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Retinol-binding protein 4Homo sapiens (human)EC50 (µMol)2.37200.14501.25852.3720AID606066
Retinol-binding protein 4Homo sapiens (human)Kd0.15600.15600.18400.2140AID606062
ProsaposinHomo sapiens (human)Kd6.90006.90006.90006.9000AID1695703; AID1695705
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (358)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
eye developmentRetinol-binding protein 4Homo sapiens (human)
positive regulation of immunoglobulin productionRetinol-binding protein 4Homo sapiens (human)
gluconeogenesisRetinol-binding protein 4Homo sapiens (human)
heart developmentRetinol-binding protein 4Homo sapiens (human)
visual perceptionRetinol-binding protein 4Homo sapiens (human)
maintenance of gastrointestinal epitheliumRetinol-binding protein 4Homo sapiens (human)
lung developmentRetinol-binding protein 4Homo sapiens (human)
positive regulation of insulin secretionRetinol-binding protein 4Homo sapiens (human)
response to retinoic acidRetinol-binding protein 4Homo sapiens (human)
retinol transportRetinol-binding protein 4Homo sapiens (human)
retinol metabolic processRetinol-binding protein 4Homo sapiens (human)
glucose homeostasisRetinol-binding protein 4Homo sapiens (human)
embryonic organ morphogenesisRetinol-binding protein 4Homo sapiens (human)
embryonic skeletal system developmentRetinol-binding protein 4Homo sapiens (human)
cardiac muscle tissue developmentRetinol-binding protein 4Homo sapiens (human)
female genitalia morphogenesisRetinol-binding protein 4Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationRetinol-binding protein 4Homo sapiens (human)
embryonic retina morphogenesis in camera-type eyeRetinol-binding protein 4Homo sapiens (human)
uterus developmentRetinol-binding protein 4Homo sapiens (human)
vagina developmentRetinol-binding protein 4Homo sapiens (human)
urinary bladder developmentRetinol-binding protein 4Homo sapiens (human)
heart trabecula formationRetinol-binding protein 4Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
sphingolipid metabolic processProsaposinHomo sapiens (human)
lysosomal transportProsaposinHomo sapiens (human)
regulation of autophagyProsaposinHomo sapiens (human)
positive regulation of beta-galactosidase activityProsaposinHomo sapiens (human)
ganglioside GM1 transport to membraneProsaposinHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentProsaposinHomo sapiens (human)
prostate gland growthProsaposinHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayProsaposinHomo sapiens (human)
regulation of lipid metabolic processProsaposinHomo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
neural tube closureRetinoic acid receptor gamma Homo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor gamma Homo sapiens (human)
growth plate cartilage chondrocyte growthRetinoic acid receptor gamma Homo sapiens (human)
apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
regulation of cell sizeRetinoic acid receptor gamma Homo sapiens (human)
anterior/posterior pattern specificationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of gene expressionRetinoic acid receptor gamma Homo sapiens (human)
embryonic camera-type eye developmentRetinoic acid receptor gamma Homo sapiens (human)
regulation of myelinationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of chondrocyte differentiationRetinoic acid receptor gamma Homo sapiens (human)
response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
embryonic hindlimb morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
multicellular organism growthRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of programmed cell deathRetinoic acid receptor gamma Homo sapiens (human)
regulation of myeloid cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
embryonic eye morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
canonical Wnt signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
face developmentRetinoic acid receptor gamma Homo sapiens (human)
trachea cartilage developmentRetinoic acid receptor gamma Homo sapiens (human)
prostate gland epithelium morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
Harderian gland developmentRetinoic acid receptor gamma Homo sapiens (human)
cellular response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cellular response to leukemia inhibitory factorRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
regulation of vasoconstrictionAlpha-1A adrenergic receptorBos taurus (cattle)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorBos taurus (cattle)
regulation of cardiac muscle contractionAlpha-1A adrenergic receptorBos taurus (cattle)
positive regulation of cholesterol effluxRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transporter activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-alphaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-alphaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-betaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-betaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-betaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-betaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-gammaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-gammaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-gammaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (109)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingRetinol-binding protein 4Homo sapiens (human)
retinal bindingRetinol-binding protein 4Homo sapiens (human)
retinol bindingRetinol-binding protein 4Homo sapiens (human)
retinol transmembrane transporter activityRetinol-binding protein 4Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protease bindingProsaposinHomo sapiens (human)
protein bindingProsaposinHomo sapiens (human)
phospholipid bindingProsaposinHomo sapiens (human)
enzyme activator activityProsaposinHomo sapiens (human)
protein homodimerization activityProsaposinHomo sapiens (human)
scaffold protein bindingProsaposinHomo sapiens (human)
ganglioside GM1 bindingProsaposinHomo sapiens (human)
ganglioside GM2 bindingProsaposinHomo sapiens (human)
ganglioside GM3 bindingProsaposinHomo sapiens (human)
ganglioside GT1b bindingProsaposinHomo sapiens (human)
ganglioside GP1c bindingProsaposinHomo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor gamma Homo sapiens (human)
DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
chromatin bindingRetinoic acid receptor gamma Homo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor gamma Homo sapiens (human)
protein bindingRetinoic acid receptor gamma Homo sapiens (human)
zinc ion bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear retinoid X receptor bindingRetinoic acid receptor gamma Homo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear receptor activityRetinoic acid receptor gamma Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorBos taurus (cattle)
vitamin D response element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription coregulator bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
peptide bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
identical protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear vitamin D receptor bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA binding domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
LBD domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-betaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-gammaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
molecular condensate scaffold activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (82)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionRetinol-binding protein 4Homo sapiens (human)
extracellular spaceRetinol-binding protein 4Homo sapiens (human)
extracellular exosomeRetinol-binding protein 4Homo sapiens (human)
extracellular spaceRetinol-binding protein 4Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
extracellular regionProsaposinHomo sapiens (human)
extracellular spaceProsaposinHomo sapiens (human)
lysosomeProsaposinHomo sapiens (human)
lysosomal membraneProsaposinHomo sapiens (human)
late endosomeProsaposinHomo sapiens (human)
plasma membraneProsaposinHomo sapiens (human)
azurophil granule membraneProsaposinHomo sapiens (human)
lysosomal lumenProsaposinHomo sapiens (human)
intracellular membrane-bounded organelleProsaposinHomo sapiens (human)
collagen-containing extracellular matrixProsaposinHomo sapiens (human)
extracellular exosomeProsaposinHomo sapiens (human)
lysosomeProsaposinHomo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
nucleoplasmRetinoic acid receptor gamma Homo sapiens (human)
cytoplasmRetinoic acid receptor gamma Homo sapiens (human)
membraneRetinoic acid receptor gamma Homo sapiens (human)
chromatinRetinoic acid receptor gamma Homo sapiens (human)
transcription regulator complexRetinoic acid receptor gamma Homo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
nucleusAlpha-1A adrenergic receptorBos taurus (cattle)
cytoplasmAlpha-1A adrenergic receptorBos taurus (cattle)
plasma membraneAlpha-1A adrenergic receptorBos taurus (cattle)
caveolaAlpha-1A adrenergic receptorBos taurus (cattle)
nuclear membraneAlpha-1A adrenergic receptorBos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
mitochondrionRetinoic acid receptor RXR-alphaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-alphaHomo sapiens (human)
receptor complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleusRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleolusRetinoic acid receptor RXR-betaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-betaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-betaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-gammaHomo sapiens (human)
cytoplasmRetinoic acid receptor RXR-gammaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (247)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1631430Inhibition of biotinylated Imp-alpha/beta1 (unknown origin) binding to Dengue virus NS5 by alpha screen assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1695706Binding affinity to human saposin D (1 to 81 residues) expressed in Escherichia coli complexed with CerOH assessed as decrease in ceramide hydrolysis using ceramide as counter-substrate measured after 24 hrs in presence of acid ceramidase by fluorescence
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID84861Reversal of keratinization in vitamin A deficient hamster trachea culture1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N-(Retinoyl)amino acids. Synthesis and chemopreventive activity in vitro.
AID521215Antiproliferative activity against mouse neural precursor cells by colony formation assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID767647Induction of RECK mRNA expression in human HT1080 cells at 1 uM after 24 hrs by RT-PCR analysis relative to control2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID1153677Reduction in RBP4 level in chow-fed B6D2F1 mouse at 5 uM after 4 hrs2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
AID717846Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID654488Cytotoxicity against human HuCCT1 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID606161Antagonist activity at His-tagged recombinant human sRBP expressed in Escherichia coli BL21(DE3) assessed as disruption of ROH-sRBP-TTR protein interaction after 2 hr by TR-FRET assay relative to control2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
AID606062Binding affinity to His-tagged recombinant human sRBP expressed in Escherichia coli BL21(DE3) assessed as apparent dissociation constant after 5 mins by fluorescence spectrophotometric analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
AID767631Toxicity in human HT1080 cells assessed as reduction of cell growth at 1 uM after 24 hrs2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID19234Partition coefficient (logP)2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
HINT predictive analysis of binding between retinol binding protein and hydrophobic ligands.
AID1364952Antiviral activity against Chikungunya virus LR2006-OPY1 infected in human Huh7.5 cells after 48 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1464506Cell cycle arrest in human SK-N-AS cells assessed as increase in sub-G1 phase population at 4 uM after 24 hrs by propidium iodide staining based flow cytometry relative to control
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1364955Selectivity index, ratio of CC50 for BHK21 cells to EC50 for Chikungunya virus2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID186913Effect on total mammary tumor volume in female rats on day 7 after a diet additive of 2 mmol/kg (+/-S.E) (p<0.05)2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID1464523Reduction in N-myc mRNA expression level in human IMR32 cells at 4 uM after 8 hrs by real-time PCR method
AID186911Effect on total mammary tumor volume in female rats on day 14 after a diet additive of 2 mmol/kg (+/-S.E) (p<0.05)2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID654645Inhibition of Akt phosphorylation in human HuCCT1 cells assessed as reduction in phospho-Akt levels at 6 uM after 48 hrs by immunoblotting2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID1187717Inhibition of lipid peroxidation in rat liver microsomes2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Inhibitory effects of p-alkylaminophenol on melanogenesis.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID717845Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID284541Growth inhibition of human estrogen receptor expressing MCF7 cells at 4 uM after 68 hrs relative to control2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
AID284545Growth inhibition of human HL60 cells at 4 uM after 72 hrs relative to control2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1695704Binding affinity to human saposin D (1 to 81 residues) expressed in Escherichia coli assessed as association constant at equilibrium at 25 degree C by fluorescence quenching spectroscopy
AID1464513Induction of apoptosis in human SK-N-AS cells assessed as increase in caspase-3 activity at 4 uM by CPP32 based colorimetric assay
AID1364956Selectivity index, ratio of CC50 for human Huh7.5 cells to EC50 for Chikungunya virus2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1153670Mean residence time in mouse at 30 mg/kg, po2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
AID445386Binding affinity to reindeer beta-lactoglobulin by fluorescence spectroscopy2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID1181357Inhibition of mushroom tyrosinase using L-tyrosine as substrate at 50 uM by spectrophotometry relative to control2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Effect of p-aminophenols on tyrosinase activity.
AID1695702Binding affinity to human saposin D (1 to 81 residues) expressed in Escherichia coli assessed as association constant at equilibrium at 25 degree C by electronic absorption spectroscopy
AID282376Growth inhibition of human LNCaP cells after 6 days by MTT assay2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID1153663Mean residence time in rat at 0.5 mg/kg, iv2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
AID170875Percentage change in DMBA-induced mammary tumor in rats;Two new tumors, partial regression in 10/14 tumors2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID344002Cytotoxicity against INI1 gene deficient human MON cells assessed as cell survival after 3 days by MTS assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors.
AID1153668AUC in mouse at 30 mg/kg, po2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
AID654644Inhibition of ERK phosphorylation in human HuCCT1 cells assessed as reduction in phospho-ERK levels at 6 uM after 48 hrs by immunoblotting2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID654483Growth inhibition of human MIAPaCa2 cells at 10 uM after 72 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID282374Growth inhibition of human MDA-MB-231 cells after 6 days by MTT assay2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID145584Efficacy is growth inhibition activity at 10 uM concentration relative to the maximum activity observed for 4-HPR with OVCAR-3 cell line2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1364954Cytotoxicity against human Huh7.5 cells in presence of ATP by Celltiter-Glo assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID282366Inhibition of ATRA hydroxylase in Syrian golden hamster liver microsome assessed ATRA metabolism using [11.12-3H]-ATRA2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID445390Binding affinity to bovine beta-lactoglobulins assessed as aggregate diameter size formed at 200 uM by dynamic light scattering method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID1464493Growth inhibition of human IMR32 cells at 0.01 uM after 72 hrs by MTT assay relative to control
AID1364951Antiviral activity against Chikungunya virus LR2006-OPY1 infected in BHK21 cells after 48 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID654484Growth inhibition of human HuCCT1 cells at 4 uM after 72 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID282367Inhibition of ATRA-induced CYP26 in human MCF7 cells assessed ATRA as metabolism using [11.12-3H]-ATRA2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID73356Binding affinity for retinoic acid receptor RAR gamma2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID1464519Induction of apoptosis in human IMR32 cells assessed as decrease in Bcl-2 mRNA expression level at 4 uM after 8 hrs by real-time PCR method
AID284542Growth inhibition of human estrogen receptor deficient adriamycin-resistant MCF7 cells at 4 uM after 68 hrs relative to control2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
AID654499Downregulation of H-ras in human HuCCT1 cells at 6 uM after 72 hrs by agarose gel electrophoresis2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID767646Reduction of MMP2 mRNA level in human HT1080 cells at 1 uM after 24 hrs by RT-PCR analysis relative to control2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID654495Downregulation of K-ras in human HuCCT1 cells at 2 uM after 72 hrs by agarose gel electrophoresis2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID1153664Volume of distribution at steady state in rat at 0.5 mg/kg, iv2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID445387Binding affinity to bovine beta-lactoglobulins at 100 uM by ultrafiltration/HPLC method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID192004Initial DMBA-induced mammary tumor volume in rat after retinoid treatment at 2 mmol/kg diet2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID150573Inhibition of TPA-induced ODC activity as percentage of the average no. of papillomas / mouse in groups of control mice was determined using papilloma assay1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Cancer chemopreventive 3-substituted-4-oxoretinoic acids.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1464522Reduction in N-myc mRNA expression level in human IMR32 cells at 4 uM after 24 hrs by real-time PCR method relative to control
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1199794Growth inhibition of human CWR22Rv1 cells by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID1464492Growth inhibition of human IMR32 cells at 0.4 uM after 72 hrs by MTT assay relative to control
AID202645Potency of compound was determined from ability to inhibit the growth of ovarian carcinoma SK-OV-3 cell line2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.
AID199394Dissociation constant with retinol binding protein was determined2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
HINT predictive analysis of binding between retinol binding protein and hydrophobic ligands.
AID49994Potency of compound was determined from ability to inhibit the growth of ovarian carcinoma cell line Caov-32004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.
AID186910Effect on total mammary tumor volume in female rats on day 1 after a diet additive of 2 mmol/kg (+/-S.E) (p<0.05)2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID1464511Induction of apoptosis in human SK-N-AS cells assessed as increase in caspase-3 activity at 4 uM after 24 hrs by CPP32 based colorimetric assay relative to control
AID202523Efficacy is growth inhibition activity at 10 uM concentration relative to the maximum activity observed for 4-HPR with SK-OV-3 cell line2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.
AID445391Solubility in DMSO assessed as aggregate diameter size at 200 uM by dynamic light scattering method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID1845990Antiproliferative activity against human Daoy cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID717840Inhibition of mouse Tdo2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 100 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1277484Cytotoxicity against human PC3 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II).
AID654482Growth inhibition of human MIAPaCa2 cells at 4 uM after 72 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID445388Binding affinity to reindeer beta-lactoglobulin at 100 uM by ultrafiltration/HPLC method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID606163Binding affinity to immobilized His-tagged recombinant human sRBP assessed as inhibition of sRBP and detergent treated HEK293 membrane interaction at 100 uM after 1 hr by surface plasmon resonance assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1199786Growth inhibition of human MDA-MB-231 cells by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID1199793Growth inhibition of human LNCAP cells by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID1695707Binding affinity to human saposin D (1 to 81 residues) expressed in Escherichia coli complexed with CerPO4 assessed as decrease in ceramide hydrolysis using ceramide as counter-substrate preincubated the protein-ceramide complex for 30 mins measured after
AID282377Growth inhibition of human PC3 cells after 6 days by MTT assay2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID521210Ratio of EC50 for mouse astrocytes to EC50 for mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1153660Metabolic stability in rat liver microsomes assessed as compound remaining after 30 mins2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID192003Final DMBA-induced mammary tumor volume in rat after retinoid treatment at 2 mmol/kg diet2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID186912Effect on total mammary tumor volume in female rats on day 21 after a diet additive of 2 mmol/kg (+/-S.E) (p<0.05)2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID1464488Growth inhibition of human SK-N-AS cells at 1 uM after 24 hrs by MTT assay relative to control
AID282373Growth inhibition of human T47D cells after 6 days by MTT assay2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID406759Cytotoxicity against human MON cells after 3 days by MTS assay2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Design and synthesis of 4-HPR derivatives for rhabdoid tumors.
AID654647Induction of apoptosis in human MIAPaCa2 cells after 72 hrs2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID654496Downregulation of K-ras in human HuCCT1 cells at 6 uM after 72 hrs by agarose gel electrophoresis2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID150571In vivo inhibition of ornithine de-carboxylase (ODC) activity induced by 12-0-tetradecanoylphorbol 13-acetate (TPA) in mouse skin1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Cancer chemopreventive 3-substituted-4-oxoretinoic acids.
AID767628Inhibition of MMP2 activity in human HT1080 cells at 1 uM after 24 hrs2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID1153666Cmax in mouse at 30 mg/kg, po2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID767630Antiinvasive activity in human HT1080 cells assessed as reduction of cell number at 1 uM after 22 hrs by matrigel invasion assay2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID1153678Reduction in retinol level in chow-fed B6D2F1 mouse at 5 uM after 4 hrs2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
AID305366Growth inhibition of human MCF7 cells at 10 uM after 48 hrs by fluorescein diacetate cell viability assay relative to 4-HPR2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs.
AID35839Binding affinity for retinoic acid receptor RAR alpha2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID1695701Binding affinity to human saposin D (1 to 81 residues) expressed in Escherichia coli assessed as decrease in BODIPY-TR labeled ceramide solubilization in sodium phosphate buffer measured after 30 mins by fluorescence assay
AID654487Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID1464487Growth inhibition of human SK-N-AS cells by MTT assay
AID654648Induction of apoptosis in human HuCCT1 cells after 72 hrs2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID388284Antiproliferative activity against human DU145 cells at 10 uM after 48 hrs by trypan blue assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID1153662AUC in rat at 0.5 mg/kg, iv2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
AID49993Efficacy is growth inhibition activity at 10 uM concentration relative to the maximum activity observed for 4-HPR with Caov-3 cell line2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.
AID1464517Induction of apoptosis in human SK-N-AS cells assessed as decrease in Bcl-2 mRNA expression level at 4 uM after 24 hrs by real-time PCR method relative to control
AID521209Antiproliferative activity against mouse astrocyte cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID199055Binding affinity against Retinoic acid receptor gamma2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID1199785Growth inhibition of human MCF7 cells by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID1199795Growth inhibition of human PC3 cells by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID521214Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID654504Inhibition of ERK phosphorylation in human MIAPaCa2 cells assessed as reduction in phospho-ERK levels at 7 uM after 48 hrs by immunoblotting2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID282372Growth inhibition of human MCF7 cells after 6 days by MTT assay2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID1695703Binding affinity to human saposin D (1 to 81 residues) expressed in Escherichia coli at 25 degree C by electronic absorption spectroscopy
AID344004Cytotoxicity against human STM cells assessed as cell survival after 3 days by MTS assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors.
AID344003Cytotoxicity against human G401 cells assessed as cell survival after 3 days by MTS assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors.
AID1364957Antiviral activity against Chikungunya virus at 0.006 to 300 uM by cell based luciferase reporter gene assay relative to control2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID344005Cytotoxicity against human MON cells assessed as cell survival after 3 days by MTS assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors.
AID767623Reduction of MMP9 mRNA level in human HT1080 cells at 1 uM after 24 hrs by RT-PCR analysis relative to control2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1199787Growth inhibition of human MDA-MB-468 cells by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID1277491Drug metabolism in human Jurkat cells assessed as DES1-mediated (2E,4E,6E,8E)-3,7-dimethyl-N-(4-oxocyclohexa-2,5-dienylidene)-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide formation2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II).
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID606162Antagonist activity at His-tagged recombinant human sRBP expressed in Escherichia coli BL21(DE3) assessed as disruption of sRBP-TTR protein interaction after 2 hr by surface plasmon resonance assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
AID1464518Induction of apoptosis in human IMR32 cells assessed as decrease in Bcl-2 mRNA expression level at 4 uM after 24 hrs by real-time PCR method relative to control
AID193324% change in the mean tumor volume in female rats on 21 days after a diet additive of 2 mmol/kg of the compound2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1464490Growth inhibition of human IMR32 cells at 0.1 uM after 24 hrs by MTT assay relative to control
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1695708Binding affinity to human saposin D (1 to 81 residues) expressed in Escherichia coli assessed as inhibition of ceramide hydrolysis preincubated for 30 mins followed by ceramide addition measured after 72 hrs by HPLC analysis
AID1364953Cytotoxicity against BHK21 cells in presence of ATP by Celltiter-Glo assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID445389Solubility assessed as lowest drug level in which detectable aggregates formed by dynamic light scattering method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID654494Downregulation of K-ras in human MIAPaCa2 cells at 7 uM after 72 hrs by agarose gel electrophoresis2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID445385Binding affinity to bovine beta-lactoglobulins by fluorescence spectroscopy2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1695709Inhibition of acid ceramidase (unknown origin) assessed as inhibition of ceramide hydrolysis preincubated for 30 mins followed by ceramide addition measured after 72 hrs by HPLC analysis
AID1845991Antiproliferative activity against human ONS-76 cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID606065Binding affinity to His-tagged recombinant human sRBP expressed in Escherichia coli BL21(DE3) assessed as disruption of sRBP-TTR protein interaction at 100 uM after 1 hr by SDS-PAGE and silver staining method relative to 10 uM ROH2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
AID521208Antiproliferative activity against mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1153661Clearance in rat at 0.5 mg/kg, iv2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
AID1695705Binding affinity to human saposin D (1 to 81 residues) expressed in Escherichia coli at 25 degree C by fluorescence quenching spectroscopy
AID41913Binding affinity for retinoic acid receptor RAR beta2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
AID282369Inhibition of ATRA-induced CYP26 in human T47D cell microsome assessed as ATRA metabolism using [11.12-3H]-ATRA2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID284544Growth inhibition of human DU145 cells at 4 uM after 68 hrs relative to control2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
AID767629Inhibition of MMP9 activity in human HT1080 cells at 1 uM after 24 hrs2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
AID654643Inhibition of Akt phosphorylation in human MIAPaCa2 cells assessed as effect on phospho-ERK levels at 7 uM after 48 hrs by immunoblotting2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID654485Growth inhibition of human HuCCT1 cells at 10 uM after 72 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1199788Growth inhibition of human SKBR3 cells by MTT assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
AID282368Inhibition of ATRA-induced CYP26 in human T47D cells assessed as ATRA metabolism using [11.12-3H]-ATRA2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID445393Solubility assessed as aggregate formation at >= pH 5 by dynamic light scattering method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID606066Antagonist activity at His-tagged recombinant human sRBP expressed in Escherichia coli BL21(DE3) assessed as disruption of ROH-sRBP-TTR protein interaction after 2 hr by TR-FRET assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.
AID145585Potency of compound was determined from ability to inhibit the growth of ovarian carcinoma OVCAR-3 cell line2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.
AID1464491Growth inhibition of human IMR32 cells at 0.1 uM after 72 hrs by MTT assay relative to control
AID1464503Cell cycle arrest in human SK-N-AS cells at 4 uM up to 72 hrs by propidium iodide staining based flow cytometry
AID284543Growth inhibition of human HepG2 cells at 4 uM after 68 hrs relative to control2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
AID717725Cytotoxicity against HEK293T cells assessed as decrease in cell viability at 25 uM after 24 hrs by trypan blue exclusion assay2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID654493Downregulation of K-ras in human MIAPaCa2 cells at 10 uM after 72 hrs by agarose gel electrophoresis2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
AID1464489Growth inhibition of human SK-N-AS cells at 1 uM after 72 hrs by MTT assay relative to control
AID1181358Inhibition of mushroom tyrosinase using L-DOPA as substrate at 50 uM by spectrophotometry relative to control2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Effect of p-aminophenols on tyrosinase activity.
AID1631432Antiviral activity against Dengue virus 1 infected in human PBMC assessed as reduction in viral titer after 48 hrs preincubated with cells prior to ADE-mediated viral infection by plaque assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1631431Inhibition of biotinylated Imp-alpha IBB deletion mutant (51 to 529 residues) (unknown origin) binding to Dengue virus NS5 by alpha screen assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (836)

TimeframeStudies, This Drug (%)All Drugs %
pre-199055 (6.58)18.7374
1990's184 (22.01)18.2507
2000's345 (41.27)29.6817
2010's209 (25.00)24.3611
2020's43 (5.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.61 (24.57)
Research Supply Index6.88 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index54.93 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials93 (10.56%)5.53%
Reviews77 (8.74%)6.00%
Case Studies9 (1.02%)4.05%
Observational0 (0.00%)0.25%
Other702 (79.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (46)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
APPLAUD: A Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Cystic Fibrosis in Adults [NCT03265288]Phase 2166 participants (Actual)Interventional2018-10-10Completed
RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease [NCT04417257]Phase 2/Phase 3125 participants (Actual)Interventional2020-06-29Active, not recruiting
An Adaptive Phase I Intra-patient Dose Escalation Study of Fenretinide in Adult Cystic Fibrosis Patients [NCT02141958]Phase 115 participants (Actual)Interventional2014-04-30Completed
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma [NCT00006080]Phase 20 participants Interventional2000-09-25Completed
Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL) [NCT02495415]Phase 2140 participants (Anticipated)Interventional2016-12-31Recruiting
Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients With Recurrent or Resistant Neuroblastoma (IND #68,254) [NCT02163356]Phase 14 participants (Actual)Interventional2014-05-31Terminated(stopped due to drug supply)
"A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058" [NCT01187810]Phase 13 participants (Actual)Interventional2010-08-31Terminated(stopped due to drug supply)
A Phase I Study of Intravenous (Emulsion) Fenretinide in Children With Recurrent or Resistant Neuroblastoma [NCT00646230]Phase 117 participants (Actual)Interventional2006-12-31Completed
A Phase Two Study Of Fenretinide In Renal Cell Cancer [NCT00011973]Phase 20 participants Interventional2000-12-31Completed
A Phase II Double-Blind Study of Topical Tretinoin With or Without Oral 4-HPR (Fenretinide) in Patients With the Dysplastic Nevus Syndrome [NCT00003601]Phase 238 participants (Anticipated)Interventional1999-02-23Completed
Breast Cancer Prevention With Fenretinide in Young Women at Genetic and Familil Risk. A Phase III Randomized Clinical Trial [NCT01479192]Phase 320 participants (Actual)Interventional2009-12-31Terminated(stopped due to very low rate of patient accrual)
A Phase 1a, Randomized, Double-blind Placebo-controlled Study to Evaluate Safety and Tolerability and to Characterize the Pharmacokinetic Profile of Single Ascending Doses of Fenretinide Oral Capsules in Healthy Adult Volunteers [NCT06181760]Phase 124 participants (Anticipated)Interventional2023-11-22Recruiting
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Malignant Solid Tumors [NCT00387504]Phase 121 participants (Anticipated)Interventional2006-11-30Completed
A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer [NCT00001378]Phase 175 participants Interventional1994-01-31Completed
A Phase I Trial of Fenretinide in Combination With Paclitaxel and Cisplatin [NCT00005819]Phase 121 participants (Actual)Interventional2000-04-30Completed
An Exploratory Evaluation of Fenretinide (4-HPR) as a Chemopreventive Agent for Ovarian Carcinoma [NCT00017134]71 participants (Anticipated)Interventional2002-09-30Terminated(stopped due to Withdrawn due to poor accrual)
Comparison Efficacy of Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients: Double-blind Placebo Controlled Study [NCT00534898]Phase 30 participants InterventionalWithdrawn(stopped due to The study withdrawn due to lack financial support)
A Phase II Study of Fenretinide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck [NCT00006471]Phase 211 participants (Actual)Interventional2000-09-30Completed
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion [NCT04234048]Phase 146 participants (Anticipated)Interventional2023-12-18Recruiting
A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration [NCT00429936]Phase 2245 participants (Actual)Interventional2006-12-31Completed
Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas [NCT00589381]Phase 130 participants (Anticipated)Interventional2007-08-31Completed
A Phase II Study of Fenretinide (NSC# 374551, IND# 40294) in Children With Recurrent/Resistant High Risk Neuroblastoma [NCT00053326]Phase 270 participants (Anticipated)Interventional2003-05-31Completed
A Phase II Trial of Fenretinide (4-HPR) in Biochemically Recurrent, Hormone Naive Prostate Cancer [NCT00080899]Phase 223 participants (Actual)Interventional2004-06-30Completed
PHASE III DOUBLE-BLIND, PLACEBO-CONTROLLED, PROSPECTIVE RANDOMIZED COMPARISON OF ADJUVANT THERAPY WITH TAMOXIFEN VS. TAMOXIFEN AND FENRETINIDE IN POSTMENOPAUSAL WOMEN WITH INVOLVED AXILLARY LYMPH NODES AND POSITIVE RECEPTORS [NCT00002646]Phase 31,500 participants (Anticipated)Interventional1995-10-31Completed
A Phase II Evaluation With Correlative Studies Of Fenretinide (NSC 374551-4HPR) As A Single Agent In The Treatment Of Adult Patients With Recurrent Glioblastoma Multiforme [NCT00075491]Phase 242 participants (Actual)Interventional2003-12-31Terminated(stopped due to Administratively complete.)
A Phase 2 Study Of Fenretinide In Patients With Hormone Refractory Prostate Cancer [NCT00077402]Phase 250 participants (Anticipated)Interventional2003-11-30Completed
A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer [NCT00102635]Phase 11 participants (Actual)Interventional2005-01-20Terminated(stopped due to Slow accrual.)
Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma [NCT01535157]Phase 1/Phase 212 participants (Actual)Interventional2012-02-29Terminated(stopped due to drug combination not providing any efficacy. Will use this data in opening new trial)
A Multicenter Randomized Double-Blinded Trial for Chemoprevention of Ovarian Cancer: Modulation of Biomarkers and Spectral Properties Using Contrast Enhanced Ultrasound in High-Risk Women Using Fenretinide (4-HPR) [NCT00098800]40 participants (Anticipated)Interventional2004-10-31Completed
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies [NCT00104923]Phase 129 participants (Actual)Interventional2005-02-28Completed
A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia [NCT00003223]Phase 25 participants (Actual)Interventional1997-12-31Terminated(stopped due to Closed due to poor accrual.)
Phase II Trial Of Fenretinide (NSC-374551; IND-40, 294) In Patients With Relapsed Small Cell Lung Cancer [NCT00009971]Phase 232 participants (Actual)Interventional2000-11-30Completed
A Phase I Study Of Fenretinide Combined With Paclitaxel And Cisplatin For The Treatment Of Refractory Solid Tumors [NCT00009932]Phase 10 participants Interventional2001-01-31Active, not recruiting
Phase II Trial of Fenretinide (NSC 374551) in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma [NCT00026091]Phase 240 participants (Actual)Interventional2001-09-30Completed
Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma [NCT00295919]Phase 180 participants (Actual)Interventional2005-12-31Completed
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADAPTIVE PHASE 2/3 STUDY OF THE EFFICACY OF LAU-7b IN THE TREATMENT OF ADULTS WITH LONG COVID AND MODERATE TO SEVERE SYMPTOMS [NCT05999435]Phase 2/Phase 3204 participants (Anticipated)Interventional2023-11-20Recruiting
Expanded Access Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole in Patients With Recurrent or Resistant Neuroblastoma (IND#68,254) [NCT02075177]0 participants Expanded AccessNo longer available
Phase I Evaluation of Fenretinide (NSC# 374551) [NCT00003250]Phase 131 participants (Actual)Interventional1998-05-31Completed
A Phase I-II Trial of Fenretinide (4-HPR) + Rituximab in Patients With B-cell Lymphoma [NCT00288067]Phase 1/Phase 232 participants (Actual)Interventional2005-10-31Terminated(stopped due to NCI stopped supplying fenretinide in November of 2012.)
Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver [NCT00546455]Phase 221 participants (Actual)Interventional2007-12-31Suspended(stopped due to This study was terminated due to expired drug with possibility of re-starting in the future.)
A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 [NCT00003075]Phase 339 participants (Actual)Interventional1993-03-05Completed
Phase II Clinical Trial of N-(4-hydroxyphenyl) Retinamide (4-HPR) and Tamoxifen in Breast Neoplasia, Administration During the Period Between the Diagnostic Core Biopsy and Definitive Surgery [NCT00003099]Phase 252 participants (Actual)Interventional1996-05-31Completed
A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia [NCT00004161]Phase 230 participants (Anticipated)Interventional1997-06-30Completed
Randomized Chemoprevention Trial With 4-HPR (Fenretinide) in Superficial Bladder Cancer [NCT00004154]Phase 3111 participants (Actual)Interventional1998-07-30Completed
Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies [NCT01553071]Phase 116 participants (Actual)Interventional2016-11-30Terminated(stopped due to drug supply issues during COVID-19)
A Phase I Study of Fenretinide (NSC #374551) in Children With High Risk Solid Tumors [NCT00003191]Phase 118 participants (Actual)Interventional1998-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00080899 (2) [back to overview]PSA Response
NCT00080899 (2) [back to overview]Time to PSA Progression
NCT00288067 (2) [back to overview]Response Rates of B-Non-Hodgkin Lymphoma to the Combination of Rituximab and Fenretinide (Phase II)
NCT00288067 (2) [back to overview]Safety, in Terms of Dose-limiting Toxicity (DLT) of 2 Daily Doses of Single Agent Fenretinide (Phase I)

PSA Response

PSA normalization (PSA-N) was recorded as the best PSA response when a PSA level was undetectable (< 0.1 ng/ml), and was then subsequently confirmed by a second measurement ≥ 4 weeks later. PSA partial response (PSA-PR) was recorded if the PSA decreased by ≥ 50% from pre-treatment or baseline values and was confirmed by a second measurement made ≥ 4 weeks later. Response = PSA-N + PSA-PR. (NCT00080899)
Timeframe: Baseline to 5 years

Interventionparticipants (Number)
Arm 10

[back to top]

Time to PSA Progression

Was summarized using the product-limit (Kaplan-Meier) method. In patients whose PSA levels initially decreased, PSA progression was defined as a 25% increase over the nadir (postenrollment PSA value up to that point), and an increase in the absolute value in the PSA value of 5 ng/mL, relative to the lowest postenrollment PSA value up to that point, including the baseline PSA level - and which was confirmed by second value 3-4 weeks later. A best response of PSA-PD was recorded for those patients who did not achieve a confirmed PSA-N or PSA-PR and who experienced PSA progression within 3 months of start of treatment. (NCT00080899)
Timeframe: From the start of treatment until the date of the first documentation of PSA progression, assessed up to 5 years

Interventionmonths (Mean)
Arm 14.6

[back to top]

Response Rates of B-Non-Hodgkin Lymphoma to the Combination of Rituximab and Fenretinide (Phase II)

The trial was stratified into rituximab-naïve and rituximab pre-treated patients, and the target response rates for these groups were expected to be 30% and 10%, respectively. The numbers reported below are subjects who achieved a response of partial response or better. (NCT00288067)
Timeframe: Up to 7 years

Interventionparticipants (Number)
Fenretinide and Rituximab (Rituximab Naive)4
Fenretinide and Rituximab (Rituximab Pre Treated)0

[back to top]

Safety, in Terms of Dose-limiting Toxicity (DLT) of 2 Daily Doses of Single Agent Fenretinide (Phase I)

"A group of 3 patients would start treatment ast the dose of 900mg/m^2 BID, and if none of the 3 experienced a DLT, another 3 would then be treated at that dose. Dose Limiting Toxicity was defined as any related toxicity of grade 4 or 5 on or before the completion of 4 weeks of therapy.~Per response evaluation criteria 1999 Cheson Response Criteria for Malignant Lymphoma (CHESON99) for target lesions assessed by either CT or MRI:~Complete Response (CR): Complete disappearance of all measurable and non-measurable disease; Complete Response Unconfirmed (CRU): Complete disappearance of all measurable and non-measurable disease, with the exception of all residual nodal masses >1.5cm in Greatest Transverse Diameter (GTD) reduced by 75% in Sum of the Product of the greatest Diameters (SPD); Partial Response (PR): 50% decrease in the SPD." (NCT00288067)
Timeframe: Number of participants that experienced a dose-limiting toxicity

Interventionparticipants (Number)
Fenretinide and Rituximab0

[back to top]